CADL insider trading
Candel Therapeutics, Inc. — open-market insider buys and $1M+ sells from SEC Forms 3, 4 and 5.
Buys · last 90 days
0 · $0
Most recent buy
2026-02-26
Recent insider filings
| Filed | Insider | Type | Shares | Price | Value |
|---|
| 2026-02-26 | Manning Paul B Director | Bought | 550,458 | $5.45 | $3.0M |
| 2024-12-18 | Manning Paul B Director | Bought | 1,250,000 | $6.00 | $7.5M |
Most active insider buyers
| Insider | Role | Buys | Total bought |
|---|
| Manning Paul B | Director | 2 | $10.5M |
See CADL on the chart
Every insider buy and sell for CADL plotted on the price, the full two-year history, cluster scores and daily updates — in the members area, $29/month. A free quarterly sample of the whole dataset needs no account.
Open the browserFree sampleData from the SEC EDGAR ownership filings, refreshed daily. Only open-market purchases (transaction code P) and sales of $1M or more are shown; grants, option exercises and tax withholding are excluded because they run on schedules set years earlier. Not investment advice.